Big Cypress Acquisition Corp Announces Special Meeting of Stockholders to Approve Business Combination with SAB Biotherapeutics Registration Statement on Form S-4 Has Been Declared Effective by Securities and Exchange Commission
Stockholder Vote Scheduled for October 20, 2021
NEWS PROVIDED BY
Big Cypress Acquisition Corp Sep 23, 2021, 07:00 ET
SHARE THIS ARTICLE
MIAMI, Sept. 23, 2021 /PRNewswire/ -- Big Cypress Acquisition Corp (NASDAQ: BCYP), (Big Cypress) a publicly-traded special purpose acquisition company focused on innovative biopharmaceutical firms, today announced that it will hold a Special Meeting of stockholders (the "Special Meeting") to, among other matters, allow its stockholders to approve the proposed business combination (the "Business Combination") with SAB Biotherapeutics, Inc., (SAB), a clinical-stage biopharmaceutical company developing a novel immunotherapy platform producing targeted, high potency, fully-human polyclonal antibody therapeutics and advancing programs in infectious disease, immune system disorders and oncology. On September 22, 2021, the Securities and Exchange Commission ("SEC") declared effective Big Cypress' registration statement on Form S-4 (as amended, the "Registration Statement"), which includes a definitive proxy statement in connection with the Special Meeting of Big Cypress' stockholders. Big Cypress and SAB entered into a definitive agreement relating to the business combination on June 22, 2021, that would result in SAB becoming a public company upon the closing of the transaction.
The Special Meeting is scheduled to be held on October 20, 2021, at 10:00 a.m., Eastern Time, and will be conducted virtually via live webcast. Holders of record of Big Cypress' common stock at the close of business on the record date of September 17, 2021, may vote at the Special Meeting.
Upon the closing of the business combination, the combined company will be named SAB Biotherapeutics, Inc. (the "Combined Company"). The parties expect that the Combined Company's common stock and warrants will be listed on the Nasdaq Stock Exchange under the ticker symbols "DIVR" and "DIVRW," respectively.
Big Cypress stockholders who need assistance voting or have questions regarding the Special Meeting may contact Big Cypress' proxy solicitor, Kingsdale Advisors, by telephone toll-free at (800) 775-1986 or by email at contactus@kingsdaleadvisors.com. Banks and brokerage firms may call (416) 867-2272.
About Big Cypress Acquisition Corp. Big Cypress Acquisition Corp. is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses with a focus within the life sciences industry. Big Cypress is led by Chief Executive Officer, Chief Financial Officer and Director Samuel J. Reich. For more information, visit www.bigcypressaccorp.com.
About SAB Biotherapeutics, Inc. SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully-human polyclonal antibodies. SAB has applied advanced genetic engineering and antibody science to develop transchromosomic (Tc) Bovine™ herds that produce fully-human antibodies targeted at specific diseases, including infectious diseases such as COVID-19 and influenza, immune system disorders including type 1 diabetes and organ transplantation, and cancer. SAB's versatile DiversitAb™ platform is applicable to a wide range of serious unmet needs in human diseases. It produces natural, specifically targeted, high-potency, human polyclonal immunotherapies. SAB is currently advancing multiple clinical programs and has a number of collaborations with the US government and global pharmaceutical companies. For more information on SAB, visit: www.sabbiotherapeutics.com and follow @SABBantibody on Twitter.
Forward-Looking Statements Certain statements made herein that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook" and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding future events, the development of SAB-185, and the proposed business combination between Big Cypress and SAB. These statements are based on the current expectations of SAB and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict, will differ from assumption and are beyond the control of SAB.
